Mon. 11 Mar 2024, 7:48am ET
Benzinga
Biotech, News, Health Care, General
- Late-breaking oral presentation of a subgroup analysis in RAMP 201 Part A heavily pretreated patients receiving avutometinib and defactinib and their best response compared to most recent prior therapy
- Plenary oral presentation of preclinical efficacy of the combination of avutometinib and FAK inhibitor in a patient-derived model of low-grade serous ovarian cancer
- A trials-in-progress poster presentation outlining the details of the ongoing Phase 3 RAMP 301 trial evaluating avutometinib and defactinib in low-grade serous ovarian cancer